Vivus, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (31)

Latest Posts

About This Stock More About This Stock
Qualcomm, Inc., VIVUS, Inc. Beat Earnings Estimates
Article By: ValueWalk
Wednesday, November 4, 2015 5:43 PM EST
Qualcomm reported adjusted earnings of 91 cents per share or $1.4 billion and $5.5 billion in revenue for its fourth fiscal quarter. Vivus posted losses of 15 cents per share and $24.9 million in revenues.
In this article: VVUS, QCOM
Read
Shares Of Orexigen Soar After It Announces Improved Safety Results For Weight-Loss Drug
Article By: Terry Chrisomalis
Tuesday, March 3, 2015 2:37 PM EST
Orexigen's drug Contrave shows not only shows great safety but also shows the ability to reduce heart-related problems as compared to placebo.
In this article: OREX, ARNA, VVUS
Read
VIVUS Q4 Loss Wider Than Expected, Qsymia Disappoints
Article By: Zacks Investment Research
Wednesday, February 25, 2015 11:56 AM EST
VIVUS Inc.’s fourth-quarter 2014 loss of 25 cents per share was wider than the Zacks Consensus Estimate loss by a penny and the year-ago loss of 9 cents.
In this article: VVUS
Read
E Novo Nordisk's Saxenda Approved But Company Enters Into A Crowded Obesity Market
Article By: Terry Chrisomalis
Friday, December 26, 2014 3:58 PM EST
Saxenda Approved by the FDA to treat Obesity but faces big obstacles against many competitors.
In this article: NVO, TKPHF, OREX, ARNA, VVUS
Read
Ramifications Of Stendra's FDA Approved Label Extension
Article By: Retail Investor 360
Friday, September 19, 2014 1:36 PM EST
Great News to Investors and Patients, But What is Vivus's Ultimate Destiny
In this article: VVUS
Read

PARTNER HEADLINES

Latest Tweets for $VVUS

No tweets yet!